nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—Valrubicin—urinary bladder cancer	0.431	0.518	CbGbCtD
Dexrazoxane—TOP2B—Etoposide—urinary bladder cancer	0.25	0.301	CbGbCtD
Dexrazoxane—TOP2A—Epirubicin—urinary bladder cancer	0.0652	0.0784	CbGbCtD
Dexrazoxane—TOP2A—Etoposide—urinary bladder cancer	0.0508	0.0611	CbGbCtD
Dexrazoxane—TOP2A—Doxorubicin—urinary bladder cancer	0.0347	0.0417	CbGbCtD
Dexrazoxane—TOP2B—prostate gland—urinary bladder cancer	0.00409	0.152	CbGeAlD
Dexrazoxane—TOP2B—seminal vesicle—urinary bladder cancer	0.00346	0.128	CbGeAlD
Dexrazoxane—TOP2A—prostate gland—urinary bladder cancer	0.003	0.111	CbGeAlD
Dexrazoxane—TOP2B—smooth muscle tissue—urinary bladder cancer	0.00289	0.107	CbGeAlD
Dexrazoxane—TOP2B—renal system—urinary bladder cancer	0.00278	0.103	CbGeAlD
Dexrazoxane—TOP2B—urethra—urinary bladder cancer	0.00274	0.102	CbGeAlD
Dexrazoxane—TOP2B—female reproductive system—urinary bladder cancer	0.00223	0.0828	CbGeAlD
Dexrazoxane—TOP2B—vagina—urinary bladder cancer	0.00202	0.0748	CbGeAlD
Dexrazoxane—TOP2B—Teniposide—Etoposide—urinary bladder cancer	0.00152	0.341	CbGdCrCtD
Dexrazoxane—TOP2A—vagina—urinary bladder cancer	0.00148	0.055	CbGeAlD
Dexrazoxane—TOP2B—lymph node—urinary bladder cancer	0.0013	0.0484	CbGeAlD
Dexrazoxane—TOP2A—lymph node—urinary bladder cancer	0.000959	0.0356	CbGeAlD
Dexrazoxane—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000368	0.0825	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000368	0.0825	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000368	0.0825	CbGdCrCtD
Dexrazoxane—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000368	0.0825	CbGdCrCtD
Dexrazoxane—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000246	0.0551	CbGdCrCtD
Dexrazoxane—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000246	0.0551	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—urinary bladder cancer	0.000224	0.097	CbGpPWpGaD
Dexrazoxane—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000148	0.0011	CcSEcCtD
Dexrazoxane—Insomnia—Gemcitabine—urinary bladder cancer	0.000148	0.0011	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000146	0.00109	CcSEcCtD
Dexrazoxane—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000146	0.00108	CcSEcCtD
Dexrazoxane—Insomnia—Fluorouracil—urinary bladder cancer	0.000145	0.00108	CcSEcCtD
Dexrazoxane—Somnolence—Gemcitabine—urinary bladder cancer	0.000145	0.00108	CcSEcCtD
Dexrazoxane—Anorexia—Cisplatin—urinary bladder cancer	0.000145	0.00108	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000144	0.00107	CcSEcCtD
Dexrazoxane—Discomfort—Etoposide—urinary bladder cancer	0.000144	0.00107	CcSEcCtD
Dexrazoxane—Breast disorder—Epirubicin—urinary bladder cancer	0.000144	0.00107	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000143	0.00106	CcSEcCtD
Dexrazoxane—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000143	0.00106	CcSEcCtD
Dexrazoxane—Somnolence—Fluorouracil—urinary bladder cancer	0.000143	0.00106	CcSEcCtD
Dexrazoxane—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000142	0.00106	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000141	0.00105	CcSEcCtD
Dexrazoxane—Fatigue—Gemcitabine—urinary bladder cancer	0.000141	0.00105	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00014	0.00104	CcSEcCtD
Dexrazoxane—Pain—Gemcitabine—urinary bladder cancer	0.00014	0.00104	CcSEcCtD
Dexrazoxane—Constipation—Gemcitabine—urinary bladder cancer	0.00014	0.00104	CcSEcCtD
Dexrazoxane—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00014	0.00104	CcSEcCtD
Dexrazoxane—Pancytopenia—Methotrexate—urinary bladder cancer	0.000139	0.00104	CcSEcCtD
Dexrazoxane—Asthenia—Thiotepa—urinary bladder cancer	0.000139	0.00104	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000139	0.00103	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000139	0.00103	CcSEcCtD
Dexrazoxane—Infection—Etoposide—urinary bladder cancer	0.000138	0.00103	CcSEcCtD
Dexrazoxane—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	0.000138	0.031	CbGdCrCtD
Dexrazoxane—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000138	0.00103	CcSEcCtD
Dexrazoxane—Dysphagia—Epirubicin—urinary bladder cancer	0.000137	0.00102	CcSEcCtD
Dexrazoxane—Neutropenia—Methotrexate—urinary bladder cancer	0.000137	0.00102	CcSEcCtD
Dexrazoxane—Pruritus—Thiotepa—urinary bladder cancer	0.000137	0.00102	CcSEcCtD
Dexrazoxane—Pain—Fluorouracil—urinary bladder cancer	0.000137	0.00102	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000136	0.00102	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—urinary bladder cancer	0.000136	0.0587	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Cisplatin—urinary bladder cancer	0.000136	0.00101	CcSEcCtD
Dexrazoxane—Skin disorder—Etoposide—urinary bladder cancer	0.000135	0.00101	CcSEcCtD
Dexrazoxane—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000135	0.001	CcSEcCtD
Dexrazoxane—Breast disorder—Doxorubicin—urinary bladder cancer	0.000133	0.000989	CcSEcCtD
Dexrazoxane—Anorexia—Etoposide—urinary bladder cancer	0.000133	0.000988	CcSEcCtD
Dexrazoxane—Diarrhoea—Thiotepa—urinary bladder cancer	0.000133	0.000988	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000132	0.000985	CcSEcCtD
Dexrazoxane—Decreased appetite—Cisplatin—urinary bladder cancer	0.000132	0.000984	CcSEcCtD
Dexrazoxane—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000132	0.000984	CcSEcCtD
Dexrazoxane—Pneumonia—Methotrexate—urinary bladder cancer	0.000132	0.000979	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000131	0.000977	CcSEcCtD
Dexrazoxane—Infestation—Methotrexate—urinary bladder cancer	0.000131	0.000974	CcSEcCtD
Dexrazoxane—Infestation NOS—Methotrexate—urinary bladder cancer	0.000131	0.000974	CcSEcCtD
Dexrazoxane—Depression—Methotrexate—urinary bladder cancer	0.000131	0.000971	CcSEcCtD
Dexrazoxane—Pancytopenia—Epirubicin—urinary bladder cancer	0.00013	0.000971	CcSEcCtD
Dexrazoxane—Pain—Cisplatin—urinary bladder cancer	0.00013	0.000968	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00013	0.000965	CcSEcCtD
Dexrazoxane—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000129	0.00096	CcSEcCtD
Dexrazoxane—Neutropenia—Epirubicin—urinary bladder cancer	0.000128	0.000956	CcSEcCtD
Dexrazoxane—Dizziness—Thiotepa—urinary bladder cancer	0.000128	0.000954	CcSEcCtD
Dexrazoxane—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000128	0.0287	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	0.000128	0.0287	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000128	0.0287	CbGdCrCtD
Dexrazoxane—Stomatitis—Methotrexate—urinary bladder cancer	0.000128	0.000949	CcSEcCtD
Dexrazoxane—Urticaria—Fluorouracil—urinary bladder cancer	0.000128	0.000948	CcSEcCtD
Dexrazoxane—Dysphagia—Doxorubicin—urinary bladder cancer	0.000127	0.000946	CcSEcCtD
Dexrazoxane—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000127	0.000944	CcSEcCtD
Dexrazoxane—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000125	0.000933	CcSEcCtD
Dexrazoxane—Weight decreased—Epirubicin—urinary bladder cancer	0.000124	0.000925	CcSEcCtD
Dexrazoxane—Dyspnoea—Etoposide—urinary bladder cancer	0.000124	0.000924	CcSEcCtD
Dexrazoxane—Somnolence—Etoposide—urinary bladder cancer	0.000124	0.000922	CcSEcCtD
Dexrazoxane—Vomiting—Thiotepa—urinary bladder cancer	0.000123	0.000918	CcSEcCtD
Dexrazoxane—Pneumonia—Epirubicin—urinary bladder cancer	0.000123	0.000917	CcSEcCtD
Dexrazoxane—Infestation NOS—Epirubicin—urinary bladder cancer	0.000123	0.000911	CcSEcCtD
Dexrazoxane—Infestation—Epirubicin—urinary bladder cancer	0.000123	0.000911	CcSEcCtD
Dexrazoxane—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000122	0.000909	CcSEcCtD
Dexrazoxane—Headache—Thiotepa—urinary bladder cancer	0.000122	0.000904	CcSEcCtD
Dexrazoxane—Decreased appetite—Etoposide—urinary bladder cancer	0.000121	0.000901	CcSEcCtD
Dexrazoxane—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000121	0.000898	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00012	0.000895	CcSEcCtD
Dexrazoxane—Body temperature increased—Cisplatin—urinary bladder cancer	0.00012	0.000895	CcSEcCtD
Dexrazoxane—Fatigue—Etoposide—urinary bladder cancer	0.00012	0.000894	CcSEcCtD
Dexrazoxane—Stomatitis—Epirubicin—urinary bladder cancer	0.000119	0.000888	CcSEcCtD
Dexrazoxane—Constipation—Etoposide—urinary bladder cancer	0.000119	0.000887	CcSEcCtD
Dexrazoxane—Pain—Etoposide—urinary bladder cancer	0.000119	0.000887	CcSEcCtD
Dexrazoxane—Neutropenia—Doxorubicin—urinary bladder cancer	0.000119	0.000884	CcSEcCtD
Dexrazoxane—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000119	0.0266	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000119	0.0266	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000119	0.0266	CbGdCrCtD
Dexrazoxane—Haemoglobin—Methotrexate—urinary bladder cancer	0.000118	0.000879	CcSEcCtD
Dexrazoxane—Haemorrhage—Methotrexate—urinary bladder cancer	0.000118	0.000874	CcSEcCtD
Dexrazoxane—Asthenia—Gemcitabine—urinary bladder cancer	0.000117	0.000871	CcSEcCtD
Dexrazoxane—Pruritus—Gemcitabine—urinary bladder cancer	0.000115	0.000859	CcSEcCtD
Dexrazoxane—Nausea—Thiotepa—urinary bladder cancer	0.000115	0.000857	CcSEcCtD
Dexrazoxane—Weight decreased—Doxorubicin—urinary bladder cancer	0.000115	0.000856	CcSEcCtD
Dexrazoxane—Feeling abnormal—Etoposide—urinary bladder cancer	0.000115	0.000854	CcSEcCtD
Dexrazoxane—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000114	0.00085	CcSEcCtD
Dexrazoxane—Pneumonia—Doxorubicin—urinary bladder cancer	0.000114	0.000848	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000114	0.000848	CcSEcCtD
Dexrazoxane—Pruritus—Fluorouracil—urinary bladder cancer	0.000114	0.000845	CcSEcCtD
Dexrazoxane—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000113	0.000843	CcSEcCtD
Dexrazoxane—Infestation—Doxorubicin—urinary bladder cancer	0.000113	0.000843	CcSEcCtD
Dexrazoxane—TOP2A—G0 and Early G1—CCNE1—urinary bladder cancer	0.000113	0.049	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000112	0.000831	CcSEcCtD
Dexrazoxane—Urticaria—Etoposide—urinary bladder cancer	0.000111	0.000824	CcSEcCtD
Dexrazoxane—Haemoglobin—Epirubicin—urinary bladder cancer	0.000111	0.000822	CcSEcCtD
Dexrazoxane—Stomatitis—Doxorubicin—urinary bladder cancer	0.000111	0.000822	CcSEcCtD
Dexrazoxane—Abdominal pain—Etoposide—urinary bladder cancer	0.00011	0.00082	CcSEcCtD
Dexrazoxane—Body temperature increased—Etoposide—urinary bladder cancer	0.00011	0.00082	CcSEcCtD
Dexrazoxane—Haemorrhage—Epirubicin—urinary bladder cancer	0.00011	0.000818	CcSEcCtD
Dexrazoxane—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00011	0.000817	CcSEcCtD
Dexrazoxane—Asthenia—Cisplatin—urinary bladder cancer	0.000109	0.000812	CcSEcCtD
Dexrazoxane—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000109	0.000811	CcSEcCtD
Dexrazoxane—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000108	0.000806	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000108	0.000804	CcSEcCtD
Dexrazoxane—Angiopathy—Methotrexate—urinary bladder cancer	0.000107	0.000793	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—urinary bladder cancer	0.000107	0.0461	CbGpPWpGaD
Dexrazoxane—Dizziness—Fluorouracil—urinary bladder cancer	0.000106	0.000789	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000106	0.000788	CcSEcCtD
Dexrazoxane—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000106	0.000787	CcSEcCtD
Dexrazoxane—Diarrhoea—Cisplatin—urinary bladder cancer	0.000104	0.000774	CcSEcCtD
Dexrazoxane—Alopecia—Methotrexate—urinary bladder cancer	0.000104	0.000772	CcSEcCtD
Dexrazoxane—Vomiting—Gemcitabine—urinary bladder cancer	0.000104	0.000772	CcSEcCtD
Dexrazoxane—Mental disorder—Methotrexate—urinary bladder cancer	0.000103	0.000766	CcSEcCtD
Dexrazoxane—Erythema—Methotrexate—urinary bladder cancer	0.000102	0.000761	CcSEcCtD
Dexrazoxane—Malnutrition—Methotrexate—urinary bladder cancer	0.000102	0.000761	CcSEcCtD
Dexrazoxane—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000102	0.000761	CcSEcCtD
Dexrazoxane—Headache—Gemcitabine—urinary bladder cancer	0.000102	0.000761	CcSEcCtD
Dexrazoxane—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000102	0.000759	CcSEcCtD
Dexrazoxane—Vomiting—Fluorouracil—urinary bladder cancer	0.000102	0.000759	CcSEcCtD
Dexrazoxane—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000102	0.000757	CcSEcCtD
Dexrazoxane—Headache—Fluorouracil—urinary bladder cancer	0.000101	0.000748	CcSEcCtD
Dexrazoxane—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.0001	0.000746	CcSEcCtD
Dexrazoxane—Asthenia—Etoposide—urinary bladder cancer	0.0001	0.000744	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.0001	0.000744	CcSEcCtD
Dexrazoxane—Angiopathy—Epirubicin—urinary bladder cancer	9.98e-05	0.000742	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Epirubicin—urinary bladder cancer	9.91e-05	0.000737	CcSEcCtD
Dexrazoxane—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	9.91e-05	0.0222	CbGdCrCtD
Dexrazoxane—Pruritus—Etoposide—urinary bladder cancer	9.86e-05	0.000734	CcSEcCtD
Dexrazoxane—Alopecia—Epirubicin—urinary bladder cancer	9.72e-05	0.000723	CcSEcCtD
Dexrazoxane—Nausea—Gemcitabine—urinary bladder cancer	9.7e-05	0.000721	CcSEcCtD
Dexrazoxane—Vomiting—Cisplatin—urinary bladder cancer	9.67e-05	0.00072	CcSEcCtD
Dexrazoxane—Mental disorder—Epirubicin—urinary bladder cancer	9.64e-05	0.000717	CcSEcCtD
Dexrazoxane—Malnutrition—Epirubicin—urinary bladder cancer	9.57e-05	0.000712	CcSEcCtD
Dexrazoxane—Erythema—Epirubicin—urinary bladder cancer	9.57e-05	0.000712	CcSEcCtD
Dexrazoxane—Diarrhoea—Etoposide—urinary bladder cancer	9.54e-05	0.000709	CcSEcCtD
Dexrazoxane—Nausea—Fluorouracil—urinary bladder cancer	9.53e-05	0.000709	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Methotrexate—urinary bladder cancer	9.49e-05	0.000706	CcSEcCtD
Dexrazoxane—Anaemia—Methotrexate—urinary bladder cancer	9.46e-05	0.000703	CcSEcCtD
Dexrazoxane—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.44e-05	0.000702	CcSEcCtD
Dexrazoxane—Angiopathy—Doxorubicin—urinary bladder cancer	9.23e-05	0.000687	CcSEcCtD
Dexrazoxane—Malaise—Methotrexate—urinary bladder cancer	9.23e-05	0.000686	CcSEcCtD
Dexrazoxane—Dizziness—Etoposide—urinary bladder cancer	9.22e-05	0.000686	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Doxorubicin—urinary bladder cancer	9.17e-05	0.000682	CcSEcCtD
Dexrazoxane—Leukopenia—Methotrexate—urinary bladder cancer	9.16e-05	0.000681	CcSEcCtD
Dexrazoxane—Nausea—Cisplatin—urinary bladder cancer	9.04e-05	0.000672	CcSEcCtD
Dexrazoxane—Alopecia—Doxorubicin—urinary bladder cancer	8.99e-05	0.000669	CcSEcCtD
Dexrazoxane—Cough—Methotrexate—urinary bladder cancer	8.93e-05	0.000664	CcSEcCtD
Dexrazoxane—Mental disorder—Doxorubicin—urinary bladder cancer	8.92e-05	0.000663	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.88e-05	0.000661	CcSEcCtD
Dexrazoxane—Vomiting—Etoposide—urinary bladder cancer	8.86e-05	0.000659	CcSEcCtD
Dexrazoxane—Malnutrition—Doxorubicin—urinary bladder cancer	8.86e-05	0.000659	CcSEcCtD
Dexrazoxane—Erythema—Doxorubicin—urinary bladder cancer	8.86e-05	0.000659	CcSEcCtD
Dexrazoxane—Anaemia—Epirubicin—urinary bladder cancer	8.85e-05	0.000658	CcSEcCtD
Dexrazoxane—Headache—Etoposide—urinary bladder cancer	8.73e-05	0.00065	CcSEcCtD
Dexrazoxane—Myalgia—Methotrexate—urinary bladder cancer	8.71e-05	0.000648	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.65e-05	0.000643	CcSEcCtD
Dexrazoxane—Malaise—Epirubicin—urinary bladder cancer	8.63e-05	0.000642	CcSEcCtD
Dexrazoxane—Discomfort—Methotrexate—urinary bladder cancer	8.61e-05	0.00064	CcSEcCtD
Dexrazoxane—Syncope—Epirubicin—urinary bladder cancer	8.59e-05	0.000639	CcSEcCtD
Dexrazoxane—Leukopenia—Epirubicin—urinary bladder cancer	8.57e-05	0.000637	CcSEcCtD
Dexrazoxane—Loss of consciousness—Epirubicin—urinary bladder cancer	8.42e-05	0.000626	CcSEcCtD
Dexrazoxane—Cough—Epirubicin—urinary bladder cancer	8.35e-05	0.000621	CcSEcCtD
Dexrazoxane—Infection—Methotrexate—urinary bladder cancer	8.3e-05	0.000617	CcSEcCtD
Dexrazoxane—Nausea—Etoposide—urinary bladder cancer	8.28e-05	0.000616	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Doxorubicin—urinary bladder cancer	8.22e-05	0.000611	CcSEcCtD
Dexrazoxane—Nervous system disorder—Methotrexate—urinary bladder cancer	8.19e-05	0.000609	CcSEcCtD
Dexrazoxane—Anaemia—Doxorubicin—urinary bladder cancer	8.19e-05	0.000609	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.18e-05	0.000608	CcSEcCtD
Dexrazoxane—Myalgia—Epirubicin—urinary bladder cancer	8.15e-05	0.000606	CcSEcCtD
Dexrazoxane—Skin disorder—Methotrexate—urinary bladder cancer	8.11e-05	0.000603	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.1e-05	0.000602	CcSEcCtD
Dexrazoxane—Discomfort—Epirubicin—urinary bladder cancer	8.05e-05	0.000599	CcSEcCtD
Dexrazoxane—Malaise—Doxorubicin—urinary bladder cancer	7.99e-05	0.000594	CcSEcCtD
Dexrazoxane—Dry mouth—Epirubicin—urinary bladder cancer	7.97e-05	0.000593	CcSEcCtD
Dexrazoxane—Anorexia—Methotrexate—urinary bladder cancer	7.96e-05	0.000592	CcSEcCtD
Dexrazoxane—Syncope—Doxorubicin—urinary bladder cancer	7.94e-05	0.000591	CcSEcCtD
Dexrazoxane—Leukopenia—Doxorubicin—urinary bladder cancer	7.93e-05	0.00059	CcSEcCtD
Dexrazoxane—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.79e-05	0.000579	CcSEcCtD
Dexrazoxane—Infection—Epirubicin—urinary bladder cancer	7.76e-05	0.000577	CcSEcCtD
Dexrazoxane—Cough—Doxorubicin—urinary bladder cancer	7.73e-05	0.000575	CcSEcCtD
Dexrazoxane—Shock—Epirubicin—urinary bladder cancer	7.69e-05	0.000572	CcSEcCtD
Dexrazoxane—Nervous system disorder—Epirubicin—urinary bladder cancer	7.66e-05	0.00057	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.65e-05	0.000569	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.61e-05	0.000566	CcSEcCtD
Dexrazoxane—Skin disorder—Epirubicin—urinary bladder cancer	7.59e-05	0.000565	CcSEcCtD
Dexrazoxane—Insomnia—Methotrexate—urinary bladder cancer	7.55e-05	0.000562	CcSEcCtD
Dexrazoxane—Myalgia—Doxorubicin—urinary bladder cancer	7.54e-05	0.000561	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.49e-05	0.000557	CcSEcCtD
Dexrazoxane—Discomfort—Doxorubicin—urinary bladder cancer	7.45e-05	0.000554	CcSEcCtD
Dexrazoxane—Anorexia—Epirubicin—urinary bladder cancer	7.45e-05	0.000554	CcSEcCtD
Dexrazoxane—Dyspnoea—Methotrexate—urinary bladder cancer	7.44e-05	0.000554	CcSEcCtD
Dexrazoxane—Somnolence—Methotrexate—urinary bladder cancer	7.42e-05	0.000552	CcSEcCtD
Dexrazoxane—Dry mouth—Doxorubicin—urinary bladder cancer	7.38e-05	0.000549	CcSEcCtD
Dexrazoxane—Decreased appetite—Methotrexate—urinary bladder cancer	7.26e-05	0.00054	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.21e-05	0.000536	CcSEcCtD
Dexrazoxane—Fatigue—Methotrexate—urinary bladder cancer	7.2e-05	0.000535	CcSEcCtD
Dexrazoxane—Infection—Doxorubicin—urinary bladder cancer	7.18e-05	0.000534	CcSEcCtD
Dexrazoxane—Pain—Methotrexate—urinary bladder cancer	7.14e-05	0.000531	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.12e-05	0.00053	CcSEcCtD
Dexrazoxane—Shock—Doxorubicin—urinary bladder cancer	7.11e-05	0.000529	CcSEcCtD
Dexrazoxane—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.09e-05	0.000527	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.08e-05	0.000527	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	7.08e-05	0.0306	CbGpPWpGaD
Dexrazoxane—Insomnia—Epirubicin—urinary bladder cancer	7.07e-05	0.000526	CcSEcCtD
Dexrazoxane—Skin disorder—Doxorubicin—urinary bladder cancer	7.02e-05	0.000522	CcSEcCtD
Dexrazoxane—Dyspnoea—Epirubicin—urinary bladder cancer	6.97e-05	0.000518	CcSEcCtD
Dexrazoxane—Somnolence—Epirubicin—urinary bladder cancer	6.95e-05	0.000517	CcSEcCtD
Dexrazoxane—Anorexia—Doxorubicin—urinary bladder cancer	6.89e-05	0.000513	CcSEcCtD
Dexrazoxane—Feeling abnormal—Methotrexate—urinary bladder cancer	6.88e-05	0.000512	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.83e-05	0.000508	CcSEcCtD
Dexrazoxane—Decreased appetite—Epirubicin—urinary bladder cancer	6.79e-05	0.000505	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.75e-05	0.000502	CcSEcCtD
Dexrazoxane—Fatigue—Epirubicin—urinary bladder cancer	6.74e-05	0.000501	CcSEcCtD
Dexrazoxane—Constipation—Epirubicin—urinary bladder cancer	6.68e-05	0.000497	CcSEcCtD
Dexrazoxane—Pain—Epirubicin—urinary bladder cancer	6.68e-05	0.000497	CcSEcCtD
Dexrazoxane—Urticaria—Methotrexate—urinary bladder cancer	6.63e-05	0.000493	CcSEcCtD
Dexrazoxane—Abdominal pain—Methotrexate—urinary bladder cancer	6.6e-05	0.000491	CcSEcCtD
Dexrazoxane—Body temperature increased—Methotrexate—urinary bladder cancer	6.6e-05	0.000491	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.59e-05	0.00049	CcSEcCtD
Dexrazoxane—Insomnia—Doxorubicin—urinary bladder cancer	6.54e-05	0.000486	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—KMT2A—urinary bladder cancer	6.51e-05	0.0282	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Doxorubicin—urinary bladder cancer	6.45e-05	0.000479	CcSEcCtD
Dexrazoxane—Feeling abnormal—Epirubicin—urinary bladder cancer	6.44e-05	0.000479	CcSEcCtD
Dexrazoxane—Somnolence—Doxorubicin—urinary bladder cancer	6.43e-05	0.000478	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.39e-05	0.000475	CcSEcCtD
Dexrazoxane—Decreased appetite—Doxorubicin—urinary bladder cancer	6.29e-05	0.000467	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.24e-05	0.000464	CcSEcCtD
Dexrazoxane—Fatigue—Doxorubicin—urinary bladder cancer	6.23e-05	0.000464	CcSEcCtD
Dexrazoxane—Urticaria—Epirubicin—urinary bladder cancer	6.21e-05	0.000462	CcSEcCtD
Dexrazoxane—Pain—Doxorubicin—urinary bladder cancer	6.18e-05	0.00046	CcSEcCtD
Dexrazoxane—Constipation—Doxorubicin—urinary bladder cancer	6.18e-05	0.00046	CcSEcCtD
Dexrazoxane—Abdominal pain—Epirubicin—urinary bladder cancer	6.18e-05	0.000459	CcSEcCtD
Dexrazoxane—Body temperature increased—Epirubicin—urinary bladder cancer	6.18e-05	0.000459	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	6.02e-05	0.026	CbGpPWpGaD
Dexrazoxane—Asthenia—Methotrexate—urinary bladder cancer	5.99e-05	0.000446	CcSEcCtD
Dexrazoxane—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.96e-05	0.000443	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.91e-05	0.00044	CcSEcCtD
Dexrazoxane—Pruritus—Methotrexate—urinary bladder cancer	5.91e-05	0.000439	CcSEcCtD
Dexrazoxane—Urticaria—Doxorubicin—urinary bladder cancer	5.74e-05	0.000427	CcSEcCtD
Dexrazoxane—Body temperature increased—Doxorubicin—urinary bladder cancer	5.72e-05	0.000425	CcSEcCtD
Dexrazoxane—Abdominal pain—Doxorubicin—urinary bladder cancer	5.72e-05	0.000425	CcSEcCtD
Dexrazoxane—Diarrhoea—Methotrexate—urinary bladder cancer	5.71e-05	0.000425	CcSEcCtD
Dexrazoxane—Asthenia—Epirubicin—urinary bladder cancer	5.61e-05	0.000417	CcSEcCtD
Dexrazoxane—Pruritus—Epirubicin—urinary bladder cancer	5.53e-05	0.000411	CcSEcCtD
Dexrazoxane—Dizziness—Methotrexate—urinary bladder cancer	5.52e-05	0.000411	CcSEcCtD
Dexrazoxane—Diarrhoea—Epirubicin—urinary bladder cancer	5.35e-05	0.000398	CcSEcCtD
Dexrazoxane—Vomiting—Methotrexate—urinary bladder cancer	5.31e-05	0.000395	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	5.25e-05	0.0227	CbGpPWpGaD
Dexrazoxane—Headache—Methotrexate—urinary bladder cancer	5.23e-05	0.000389	CcSEcCtD
Dexrazoxane—Asthenia—Doxorubicin—urinary bladder cancer	5.19e-05	0.000386	CcSEcCtD
Dexrazoxane—Dizziness—Epirubicin—urinary bladder cancer	5.17e-05	0.000384	CcSEcCtD
Dexrazoxane—Pruritus—Doxorubicin—urinary bladder cancer	5.12e-05	0.00038	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—SMC1B—urinary bladder cancer	5.11e-05	0.0221	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RRM2—urinary bladder cancer	4.98e-05	0.0216	CbGpPWpGaD
Dexrazoxane—Vomiting—Epirubicin—urinary bladder cancer	4.97e-05	0.00037	CcSEcCtD
Dexrazoxane—Nausea—Methotrexate—urinary bladder cancer	4.96e-05	0.000369	CcSEcCtD
Dexrazoxane—Diarrhoea—Doxorubicin—urinary bladder cancer	4.95e-05	0.000368	CcSEcCtD
Dexrazoxane—Headache—Epirubicin—urinary bladder cancer	4.9e-05	0.000364	CcSEcCtD
Dexrazoxane—Dizziness—Doxorubicin—urinary bladder cancer	4.78e-05	0.000356	CcSEcCtD
Dexrazoxane—Nausea—Epirubicin—urinary bladder cancer	4.64e-05	0.000345	CcSEcCtD
Dexrazoxane—Vomiting—Doxorubicin—urinary bladder cancer	4.6e-05	0.000342	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	4.58e-05	0.0198	CbGpPWpGaD
Dexrazoxane—Headache—Doxorubicin—urinary bladder cancer	4.53e-05	0.000337	CcSEcCtD
Dexrazoxane—Nausea—Doxorubicin—urinary bladder cancer	4.29e-05	0.000319	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	4.17e-05	0.0181	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	4.1e-05	0.0177	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	4e-05	0.0173	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—urinary bladder cancer	3.78e-05	0.0164	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—EGFR—urinary bladder cancer	3.69e-05	0.016	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	3.49e-05	0.0151	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	3.47e-05	0.015	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	3.19e-05	0.0138	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	3.1e-05	0.0134	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	2.93e-05	0.0127	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	2.93e-05	0.0127	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	2.88e-05	0.0125	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	2.8e-05	0.0121	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	2.78e-05	0.012	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	2.62e-05	0.0113	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	2.25e-05	0.00973	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	2.22e-05	0.00963	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	2.22e-05	0.0096	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	2.22e-05	0.0096	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	2.18e-05	0.00945	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	2.1e-05	0.00908	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	2.07e-05	0.00897	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	2.06e-05	0.00893	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	2e-05	0.00864	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	1.98e-05	0.00858	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	1.98e-05	0.00858	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	1.95e-05	0.00846	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	1.94e-05	0.00838	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	1.86e-05	0.00804	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	1.83e-05	0.00791	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	1.72e-05	0.00744	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	1.71e-05	0.0074	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	1.7e-05	0.00737	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	1.7e-05	0.00734	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	1.65e-05	0.00716	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	1.63e-05	0.00708	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	1.63e-05	0.00707	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	1.55e-05	0.00672	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.49e-05	0.00643	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	1.49e-05	0.00643	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.47e-05	0.00635	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	1.45e-05	0.00628	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	1.4e-05	0.00608	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	1.39e-05	0.00601	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	1.36e-05	0.00588	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.24e-05	0.00539	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.22e-05	0.00527	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.16e-05	0.00504	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.1e-05	0.00476	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.08e-05	0.00466	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.06e-05	0.0046	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.06e-05	0.00459	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	1.06e-05	0.00458	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	1.02e-05	0.00441	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.01e-05	0.00438	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	9.84e-06	0.00426	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	9.72e-06	0.00421	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	9.62e-06	0.00417	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	9.45e-06	0.00409	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.82e-06	0.00382	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	8.63e-06	0.00373	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	8.24e-06	0.00357	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERT—urinary bladder cancer	8.23e-06	0.00356	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	8.22e-06	0.00356	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	8.15e-06	0.00353	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—ATM—urinary bladder cancer	7.4e-06	0.0032	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	7.37e-06	0.00319	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	7.24e-06	0.00314	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	7.17e-06	0.0031	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	6.95e-06	0.00301	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RB1—urinary bladder cancer	6.41e-06	0.00277	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	6.3e-06	0.00273	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	5.63e-06	0.00244	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	5.32e-06	0.0023	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	5.15e-06	0.00223	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	4.9e-06	0.00212	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	4.76e-06	0.00206	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	4.6e-06	0.00199	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—EP300—urinary bladder cancer	4.38e-06	0.0019	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	4.27e-06	0.00185	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—urinary bladder cancer	3.82e-06	0.00165	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—urinary bladder cancer	3.14e-06	0.00136	CbGpPWpGaD
